HK1047052A1 - 含有hmg還原酶抑制劑的藥物組合物 - Google Patents

含有hmg還原酶抑制劑的藥物組合物

Info

Publication number
HK1047052A1
HK1047052A1 HK02108790.3A HK02108790A HK1047052A1 HK 1047052 A1 HK1047052 A1 HK 1047052A1 HK 02108790 A HK02108790 A HK 02108790A HK 1047052 A1 HK1047052 A1 HK 1047052A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
coa reductase
reductase inhibitor
hmg coa
hmg
Prior art date
Application number
HK02108790.3A
Other languages
English (en)
Inventor
Richard Creekmore Joseph
Alfred Wiggins Norman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1047052(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1047052A1 publication Critical patent/HK1047052A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HK02108790.3A 2000-01-26 2002-12-03 含有hmg還原酶抑制劑的藥物組合物 HK1047052A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions
PCT/GB2000/003014 WO2001054668A1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg reductase inhibitor

Publications (1)

Publication Number Publication Date
HK1047052A1 true HK1047052A1 (zh) 2003-02-07

Family

ID=9884259

Family Applications (6)

Application Number Title Priority Date Filing Date
HK01107604A HK1036935A1 (en) 2000-01-26 2001-10-31 Pharmaceutical compositions.
HK01107603A HK1036934A1 (en) 2000-01-26 2001-10-31 Pharmaceutical compositions
HK02102911.0A HK1040936B (zh) 2000-01-26 2002-04-17 藥物組合物
HK02108790.3A HK1047052A1 (zh) 2000-01-26 2002-12-03 含有hmg還原酶抑制劑的藥物組合物
HK03101240.3A HK1048950A1 (zh) 2000-01-26 2003-02-18 含有一種hmg coa還原酶抑制劑的藥用組合物
HK15101088.4A HK1200368A1 (zh) 2000-01-26 2015-02-02 含有 還原酶抑制劑的藥物組合物

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HK01107604A HK1036935A1 (en) 2000-01-26 2001-10-31 Pharmaceutical compositions.
HK01107603A HK1036934A1 (en) 2000-01-26 2001-10-31 Pharmaceutical compositions
HK02102911.0A HK1040936B (zh) 2000-01-26 2002-04-17 藥物組合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK03101240.3A HK1048950A1 (zh) 2000-01-26 2003-02-18 含有一種hmg coa還原酶抑制劑的藥用組合物
HK15101088.4A HK1200368A1 (zh) 2000-01-26 2015-02-02 含有 還原酶抑制劑的藥物組合物

Country Status (48)

Country Link
US (2) US6548513B1 (zh)
EP (6) EP2018853A1 (zh)
JP (3) JP3267960B2 (zh)
KR (3) KR100388713B1 (zh)
CN (3) CN101028268A (zh)
AP (2) AP1879A (zh)
AR (3) AR023624A1 (zh)
AT (3) AT412062B (zh)
AU (5) AU6580000A (zh)
BE (2) BE1013413A3 (zh)
BG (4) BG65234B1 (zh)
BR (2) BR0003364A (zh)
CA (3) CA2313783C (zh)
CH (2) CH700184B1 (zh)
CL (1) CL2007001807A1 (zh)
CR (3) CR6568A (zh)
CZ (3) CZ298411B6 (zh)
DE (3) DE10038108A1 (zh)
DK (3) DK200001170A (zh)
EE (3) EE04990B1 (zh)
ES (2) ES2171123B1 (zh)
FI (3) FI121365B (zh)
FR (2) FR2804025B1 (zh)
GB (3) GB0001621D0 (zh)
HK (6) HK1036935A1 (zh)
HR (3) HRP20020097B1 (zh)
HU (2) HUP0003111A3 (zh)
IL (4) IL147870A (zh)
IS (3) IS1940B (zh)
IT (2) ITTO20000780A1 (zh)
ME (4) MEP33808A (zh)
MY (2) MY123650A (zh)
NL (2) NL1015858C2 (zh)
NO (4) NO312434B1 (zh)
NZ (2) NZ519774A (zh)
PL (2) PL341855A1 (zh)
PT (3) PT102503B (zh)
RS (1) RS50201B (zh)
RU (2) RU2206324C1 (zh)
SE (2) SE523481C2 (zh)
SI (1) SI1223918T1 (zh)
SK (2) SK283872B6 (zh)
TR (3) TR200200270T2 (zh)
TW (2) TWI228050B (zh)
UA (2) UA51853C2 (zh)
WO (2) WO2001054669A1 (zh)
YU (1) YU52902A (zh)
ZA (2) ZA200003998B (zh)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
ES2401598T3 (es) † 2000-04-10 2013-04-22 Teva Pharmaceutical Industries, Ltd. Composiciones farmacéuticas estables que contienen ácidos 7-sustituido-3,5-dihidroxiheptanoicos o ácidos 7-sustituido-3,5-dihidroxiheptenoicos
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
EP1541140A1 (en) * 2002-08-12 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Amino acid-containing chewable
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
CA2657076A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
JP5026077B2 (ja) * 2003-09-12 2012-09-12 アムジエン・インコーポレーテツド カルシウム受容体−活性化合物の急速溶解処方
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
CA2546701C (en) * 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
ATE507209T1 (de) * 2003-12-02 2011-05-15 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
TW200539903A (en) * 2004-03-12 2005-12-16 Smithkline Beecham Plc Pharmaceutical formulations
HUE033015T2 (en) * 2004-05-04 2017-11-28 Innophos Inc Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
JP2007508379A (ja) * 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
AU2005271407A1 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
TWI353981B (en) * 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
JP2009515816A (ja) * 2005-08-04 2009-04-16 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法
US7868169B2 (en) * 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
DK1928409T3 (da) 2005-09-12 2012-11-05 Actelion Pharmaceuticals Ltd Stabil farmaceutisk sammensætning omfattende pyrimidin-sulfamid
UA92920C2 (ru) * 2005-10-31 2010-12-27 Кова Ко., Лтд. Таблетка с насечкой, включающая питавастатин, и имеющая превосходную фотостабильность
CA2630704C (en) * 2005-12-20 2014-08-19 Lek Pharmaceuticals D.D. Pharmaceutical composition
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
WO2007125547A2 (en) * 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
HUE028475T2 (en) * 2006-10-09 2016-12-28 Msn Laboratories Private Ltd A novel process for the preparation of statins and their pharmaceutically acceptable salts
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
MX2009010925A (es) * 2007-04-09 2009-11-02 Scidose Llc Combinaciones de estatinas y agente anti-obesidad.
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
JP2011510974A (ja) * 2008-01-30 2011-04-07 ルピン・リミテッド ＨＭＧ−ＣｏＡ還元酵素阻害剤の調節放出製剤
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
CA2727630A1 (en) * 2008-06-13 2009-12-17 Glaxo Group Limited Pharmaceutical formulations
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
JP2011525901A (ja) * 2008-06-27 2011-09-29 アブディ イブラヒム イラク サナイ ベ ティカレット アノニム シルケティ ロスバスタチンカルシウム含有医薬組成物
EP2309992B1 (en) * 2008-06-27 2017-10-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
WO2011018185A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
EP2566465A2 (en) 2010-05-04 2013-03-13 Mahmut Bilgic Stable rosuvastatin formulations
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
EP2698159A4 (en) * 2011-04-12 2014-11-05 Sawai Seiyaku Kk PITAVASTATE-CONTAINING PREPARATION AND METHOD OF MANUFACTURING THEREOF
CA2835364C (en) 2011-05-20 2018-10-02 Astrazeneca Uk Limited Pharmaceutical composition of rosuvastatin calcium
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
DK2851075T3 (da) * 2012-05-14 2022-01-31 Shionogi & Co Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
CN105163734A (zh) * 2013-03-12 2015-12-16 株式会社Lg生命科学 包含缬沙坦及罗舒伐他汀钙的复合制剂及其制造方法
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
KR20170083071A (ko) * 2014-11-11 2017-07-17 시오노기 앤드 컴파니, 리미티드 광에 대해서 불안정한 약물을 함유하는 다층 정제
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
CN108472249A (zh) 2015-10-23 2018-08-31 林德拉有限公司 用于治疗剂缓释的胃驻留系统及其使用方法
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
AU2017336154B2 (en) 2016-09-30 2023-11-09 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
KR900701778A (ko) * 1988-10-06 1990-12-04 예안 크라머, 한스 루돌프 하우스 피리미디닐- 치환된 하이드록시산, 락톤 및 에스테르, 및 이를 함유하는 약학적 조성물
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
ATE112491T1 (de) 1990-09-13 1994-10-15 Akzo Nobel Nv Stabilisierte feste chemische zusammensetzungen.
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
ATE178794T1 (de) 1993-01-19 1999-04-15 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
DE122011000014I1 (de) * 1995-12-22 2011-11-03 Kowa Co Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium.
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
ATE295184T1 (de) 1998-06-05 2005-05-15 Warner Lambert Co Stabilisierung von zusammensetzungen enthaltend ace-hemmer durch magnesiumoxid
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
AR022462A1 (es) 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2396593A1 (en) 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
YU5202A (sh) 2004-12-31
FI20105657A (fi) 2010-06-10
IS6254A (is) 2002-01-29
BE1013413A3 (fr) 2001-12-04
EP2266540A1 (en) 2010-12-29
JP4800467B2 (ja) 2011-10-26
ME00191B (me) 2010-10-10
SE523481C2 (sv) 2004-04-20
BE1013414A5 (fr) 2001-12-04
AT412063B (de) 2004-09-27
PL196808B1 (pl) 2008-02-29
DK200001171A (da) 2001-07-27
AP2002002591A0 (en) 2002-09-30
TWI228050B (en) 2005-02-21
NO20071303L (no) 2001-07-27
NO327675B1 (no) 2009-09-07
EP1223918B1 (en) 2003-02-05
TR200200270T2 (tr) 2002-06-21
US6316460B1 (en) 2001-11-13
WO2001054668A1 (en) 2001-08-02
NO312434B1 (no) 2002-05-13
PT102503B (pt) 2004-02-27
CR6687A (es) 2005-07-18
DE60001371D1 (de) 2003-03-13
SE0002826D0 (sv) 2000-08-04
EE200900047A (et) 2011-04-15
CZ298411B6 (cs) 2007-09-26
NO20003967L (no) 2001-07-27
NL1015859A1 (nl) 2001-07-27
IS2805B (is) 2012-09-15
CN101028268A (zh) 2007-09-05
IS8620A (is) 2007-03-07
HUP0003111A3 (en) 2003-03-28
SE0002826L (sv) 2001-07-27
TR200201888T2 (tr) 2002-11-21
ATE232088T1 (de) 2003-02-15
NO327554B1 (no) 2009-08-10
AU5184200A (en) 2001-08-02
ZA200003997B (en) 2000-08-14
HU222578B1 (hu) 2003-08-28
CZ20002883A3 (cs) 2000-10-11
HK1200368A1 (zh) 2015-08-07
RS50201B (sr) 2009-07-15
HU0003111D0 (en) 2000-10-28
HRP20020632A2 (en) 2004-12-31
FI111806B (fi) 2003-09-30
FI20001750A (fi) 2001-07-27
ES2171123B1 (es) 2003-11-16
CN100528161C (zh) 2009-08-19
AR025055A1 (es) 2002-11-06
FI121589B (fi) 2011-01-31
GB2358583A (en) 2001-08-01
CN1319396A (zh) 2001-10-31
AU2000264559A1 (en) 2001-08-07
AP2002002409A0 (en) 2002-03-31
AU6580000A (en) 2001-08-07
ITTO20000780A1 (it) 2000-11-04
IL150513A0 (en) 2003-02-12
JP2001206877A (ja) 2001-07-31
BG106926A (bg) 2003-04-30
HUP0003110A2 (hu) 2001-05-28
NZ531474A (en) 2007-04-27
EP1251831A1 (en) 2002-10-30
HK1040936A1 (en) 2002-06-28
CA2315141C (en) 2009-08-18
UA77156C2 (en) 2006-11-15
ATA13602000A (de) 2004-02-15
PT102504A (pt) 2001-07-31
MY123650A (en) 2006-05-31
DK1223918T3 (da) 2003-04-28
FR2804025A1 (fr) 2001-07-27
IL147870A0 (en) 2002-08-14
FR2795324A1 (fr) 2000-12-29
EP2133070A1 (en) 2009-12-16
CZ299105B6 (cs) 2008-04-23
BR0003365A (pt) 2001-09-18
NL1015858C2 (nl) 2001-07-27
NL1015859C2 (nl) 2001-10-16
KR20010077840A (ko) 2001-08-20
AU2005202392B2 (en) 2008-11-20
AU738074B2 (en) 2001-09-06
EE05221B1 (et) 2009-10-15
CZ20002884A3 (cs) 2001-09-12
PL341853A1 (en) 2001-01-29
IL150513A (en) 2012-12-31
SK11782000A3 (sk) 2001-12-03
HUP0003111A2 (hu) 2002-02-28
FI20001750A0 (fi) 2000-08-04
GB0019029D0 (en) 2000-09-27
HRP20020097B1 (en) 2010-12-31
BG66159B1 (bg) 2011-09-30
CZ290167B6 (cs) 2002-06-12
GB2358583B (en) 2002-02-06
KR100388713B1 (ko) 2003-06-25
AU2005202392C1 (en) 2016-06-02
CR10114A (es) 2008-08-21
RU2002122752A (ru) 2004-03-10
MY122707A (en) 2006-04-29
FI121365B (fi) 2010-10-29
PL341855A1 (en) 2001-07-30
IL147870A (en) 2003-10-31
FI20001749A0 (fi) 2000-08-04
JP2007182452A (ja) 2007-07-19
BG65234B1 (bg) 2007-09-28
FR2795324B1 (fr) 2002-05-17
ES2155043B1 (es) 2001-12-01
IL187416A0 (en) 2008-02-09
GB2358582A (en) 2001-08-01
HK1048950A1 (zh) 2003-04-25
AR060248A2 (es) 2008-06-04
SK11792000A3 (sk) 2001-12-03
UA51853C2 (uk) 2002-12-16
ME00202B (me) 2010-10-10
HRP20080525A2 (en) 2008-12-31
HU0003110D0 (en) 2000-10-28
ES2155043A1 (es) 2001-04-16
HRP20020097A2 (en) 2002-06-30
YU52902A (sh) 2006-01-16
PT1223918E (pt) 2003-06-30
CA2639407A1 (en) 2001-07-26
EE200200411A (et) 2003-12-15
ITTO20000779A1 (it) 2002-02-04
MEP33708A (en) 2010-10-10
AU5184100A (en) 2001-08-02
CR6568A (es) 2004-03-05
DE10038110B4 (de) 2006-06-29
HK1036935A1 (en) 2002-01-25
CN1282581A (zh) 2001-02-07
AU781269C (en) 2006-11-30
CH700184B1 (de) 2010-07-15
IS6480A (is) 2002-07-23
CA2313783C (en) 2002-03-12
EP1223918A1 (en) 2002-07-24
HUP0003110A3 (en) 2003-02-28
JP4800988B2 (ja) 2011-10-26
HK1036934A1 (en) 2002-01-25
BG110353A (en) 2009-09-30
BG106393A (en) 2002-07-31
NO2010005I1 (no) 2010-05-03
FI20001749A (fi) 2001-07-27
KR20030036492A (ko) 2003-05-09
CL2007001807A1 (es) 2008-01-18
HK1040936B (zh) 2010-06-11
GB0019028D0 (en) 2000-09-27
NO20003968L (no) 2001-07-27
DK178242B1 (da) 2015-09-28
EE04990B1 (et) 2008-04-15
DK200001170A (da) 2001-01-27
EE05586B1 (et) 2012-10-15
US6548513B1 (en) 2003-04-15
PT102503A (pt) 2000-12-29
DE10038108A1 (de) 2001-08-02
TW553749B (en) 2003-09-21
AU2005202392A1 (en) 2005-06-30
TR200701171T2 (tr) 2007-04-24
MEP33808A (en) 2010-10-10
RU2206324C1 (ru) 2003-06-20
SE0002827L (sv) 2001-07-27
ZA200003998B (en) 2000-08-14
ATA13612000A (de) 2004-02-15
DE60001371T2 (de) 2004-01-22
CH691347A5 (de) 2001-07-13
ITTO20000779A0 (it) 2000-08-04
AP1879A (en) 2008-08-14
NZ519774A (en) 2004-04-30
RU2264210C2 (ru) 2005-11-20
WO2001054669A1 (en) 2001-08-02
AU781269B2 (en) 2005-05-12
AP1449A (en) 2005-07-28
SI1223918T1 (en) 2003-06-30
HRP20020632B1 (en) 2010-12-31
ES2171123A1 (es) 2002-08-16
FR2804025B1 (fr) 2002-08-23
GB0001621D0 (en) 2000-03-15
CA2639407C (en) 2011-09-13
KR20000072135A (ko) 2000-12-05
SE0002827D0 (sv) 2000-08-04
NO20003968D0 (no) 2000-08-04
SK283872B6 (sk) 2004-03-02
GB2358582B (en) 2004-09-29
KR100698333B1 (ko) 2007-03-23
AR023624A1 (es) 2002-09-04
JP2001206847A (ja) 2001-07-31
DE10038110A1 (de) 2001-08-23
CN1149997C (zh) 2004-05-19
CA2313783A1 (en) 2000-10-16
JP3267960B2 (ja) 2002-03-25
BG66168B1 (bg) 2011-10-31
EP2018853A1 (en) 2009-01-28
AT412062B (de) 2004-09-27
SE523471C2 (sv) 2004-04-20
BR0003364A (pt) 2001-09-18
CA2315141A1 (en) 2001-07-26
NO20003967D0 (no) 2000-08-04
EP2774609A1 (en) 2014-09-10
EE200200052A (et) 2003-04-15
IS1940B (is) 2004-07-16

Similar Documents

Publication Publication Date Title
HK1200368A1 (zh) 含有 還原酶抑制劑的藥物組合物
HUP0104258A3 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
HUP0301087A3 (en) Oral pharmaceutical composition comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
IL152077A0 (en) Pharmaceutical compositions comprising fluvastatin
AU2001250420A1 (en) Pharmaceutical compositions
IL154977A0 (en) Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
GB0009584D0 (en) Pharmaceutical compositions
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
EP1286702A4 (en) HMG COA REDUCTASE INHIBITORS TO PROMOTE ANGIOGENESIS
AU8576801A (en) Pharmaceutical compositions
AU1390002A (en) Pharmaceutical compositions
AU2001273919A1 (en) Pharmaceutical compositions
EP1372616A4 (en) STABLE PHARMACEUTICAL COMPOSITION BASED ON PRAVASTATIN
IL149524A0 (en) HMG-CoA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATIONS
IL144285A0 (en) Pharmaceutical compositions containing a vasopeptidase inhibitor
HUP0301728A3 (en) Hmg-coa reductase inhibiting pharmaceutical compositions and their use
HK1077230A1 (en) Medicinal composition hmg-coa reductase inhibitor
AU2001285737A1 (en) Pharmaceutical compositions
AUPQ875300A0 (en) A pharmaceutical composition
GB0003929D0 (en) Pharmaceutical compositions
GB0008872D0 (en) Pharmaceutical compositions
GB0001337D0 (en) Pharmaceutical compositions
GB0000062D0 (en) Pharmaceutical compositions